Navigation Links
Sunpeaks Ventures Announces Clotamin to Be Sold at Winn-Dixie Locations in South Florida
Date:3/30/2012

SILVER SPRING, Md., March 30, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that Clotamin® is now an authorized product at Winn-Dixie. Clotamin will be available at 57 Winn-Dixie locations in South Florida starting in May 2012.

Winn-Dixie is headquartered in Jacksonville, Florida, and currently operates 482 stores throughout Alabama, Florida, Georgia, Louisiana and Mississippi.  In addition to filling prescriptions, Winn-Dixie pharmacies also provide preventive health screenings, medication counseling, immunizations, and other services.

"Winn-Dixie stores have a long history in Florida and have built close ties within the communities they serve.  We expect that their pharmacies will make an excellent venue for showcasing Clotamin and reach their many loyal customers," stated Mackie A. Barch, CEO of Sunpeaks.  "Moving forward, we believe that our success at increasing distribution in Florida will serve as a template for expanding Clotamin sales in other regions and also nationwide."

Clotamin® is the world's first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin® or other anticoagulants (blood thinners). 

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market.   HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements.  These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements.  The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission.  All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement.  Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.


'/>"/>
SOURCE Sunpeaks Ventures, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunpeaks Ventures Completes Acquisition of Healthcare Distribution Specialists LLC
2. Sunpeaks Ventures Enters $45 Billion Specialty Drug Distribution Sector
3. Sunpeaks Ventures Announces Clotamin available on Walgreens.com
4. Sunpeaks Ventures Announces Clotamin to be Sold at Navarro Discount Pharmacies
5. Sunpeaks Ventures to Participate in ECRM Conference and Expo
6. Sunpeaks Ventures Announces Clotamin to be Sold at Bravo Supermarkets in South Florida
7. 7 Health Ventures Invests in Tulip Medical
8. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
9. ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures
10. Fulcrum Ventures Leads $1.25 Million Investment in Path-Tec, LLC
11. Phreesia to Accelerate Growth with $16 Million Investment Led by Ascension Health Ventures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):